Sanofi

Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.

The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.

Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

Sanofi a ppoints  Paulo Fontoura   as   Global  Head of  R&D Paris ,  June 22 ,   2026. Sanofi today announced the appointment of Paulo F o ntoura ,  MD, PhD, FAAN,   as  Executi v e Vice President, Global  Head of Research & Development  Pharma, effective September 1, 2026.

Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IV Second global approval for Sarclisa SC following the EU Paris, June 19, 2026. The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma (MM).

Sanofi remains a compelling investment opportunity, driven by a robust pipeline and strong fundamentals. Sarclisa sales in Q1 of 2026 grew by 30.1% to $193.21 million; expansion with on-body injector [OBI] could make a push to compete in the MM space against Darzalex. Dupixent sales in Q1 of 2026 grew by 30.8% to $4.85 billion, boosted by continued strong execution and expansion for pediatric patients in CSU.

SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

The U.S. ​Food and ‌Drug Administration approved ​Sanofi's ​injection to slow ⁠the loss ​of ​the body's own insulin production ​in ​children aged 8 ‌to ⁠17 years recently diagnosed ​with ​stage ⁠3 type ​1 ​diabetes, ⁠the agency said ⁠on ​Friday.